NCT03813290 A Neuro-Technological Intervention for Adolescents With GAD
| NCT ID | NCT03813290 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Healthcare Group, Singapore |
| Condition | Generalised Anxiety Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-12-08 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-12-08 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the safety and acceptability of a basic neuro-technological intervention in the treatment of adolescents with Generalised Anxiety Disorder (GAD). Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro- / bio-feedback-based virtual reality (VR) game interface that is driven by a novel algorithm.
Eligibility Criteria
Inclusion Criteria: * Between 13 to 18 years of age inclusive * Literate in English Language * Newly diagnosed with Generalised Anxiety Disorder: current episode, based on Computerised Diagnostic Interview Schedule for Children (C-DISC) * If on medication, dosage stable or unchanged for at least preceding 8 weeks * Has parental consent Exclusion Criteria: * Diagnosis (as defined by DSM-5) of: anxiety disorder induced by medication, substance, or another medical condition; obsessive compulsive disorder; bipolar disorder; any psychotic disorder (lifetime); intellectual disability (i.e. IQ\<70); autism spectrum disorder; attention-deficit/hyperactivity disorder * History of substance or drug use disorder (as per DSM-5 criteria) within the last 3 months * Neurological disorders or insults (e.g. epilepsy, cerebrovascular accidents) * Metal in the cranium, skull defects, or skin lesions on scalp (e.g. cuts, abrasion, rash) at proposed electrode sites * Irregular heart rhythms or heart problems * Severe visual or hearing impairment * Prior experience with mindfulness-based therapy (e.g. mindfulness-based stress reduction \[MBSR\], mindfulness-based cognitive therapy \[MBCT\])
Contact & Investigator
Lim Choon Guan
PRINCIPAL INVESTIGATOR
Institute of Mental Health, Singapore
Frequently Asked Questions
Who can join the NCT03813290 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 18 Years, studying Generalised Anxiety Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03813290 currently recruiting?
Yes, NCT03813290 is actively recruiting participants. Contact the research team at shernice_sy_lim@imh.com.sg for enrollment information.
Where is the NCT03813290 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT03813290 clinical trial?
NCT03813290 is sponsored by National Healthcare Group, Singapore. The principal investigator is Lim Choon Guan at Institute of Mental Health, Singapore. The trial plans to enroll 30 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.